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Pooled-DNA sequencing identifies novel
causative variants in PSEN1, GRN and MAPT in a
clinical early-onset and familial Alzheimer’s
disease Ibero-American cohort
Sheng Chih Jin1, Pau Pastor2,3,4, Breanna Cooper1, Sebastian Cervantes2, Bruno A Benitez1, Cristina Razquin2,
Alison Goate1, Ibero-American Alzheimer Disease Genetics Group Researchers and Carlos Cruchaga1*
Abstract
Introduction: Some familial Alzheimer’s disease (AD) cases are caused by rare and highly-penetrant mutations in
APP, PSEN1, and PSEN2. Mutations in GRN and MAPT, two genes associated with frontotemporal dementia (FTD),
have been found in clinically diagnosed AD cases. Due to the dramatic developments in next-generation
sequencing (NGS), high-throughput sequencing of targeted genomic regions of the human genome in many
individuals in a single run is now cheap and feasible. Recent findings favor the rare variant-common disease
hypothesis by which the combination effects of rare variants could explain a large proportion of the heritability.
We utilized NGS to identify rare and pathogenic variants in APP, PSEN1, PSEN2, GRN, and MAPT in an Ibero-
American cohort.
Methods: We performed pooled-DNA sequencing of each exon and flanking sequences in APP, PSEN1, PSEN2,
MAPT and GRN in 167 clinical and 5 autopsy-confirmed AD cases (15 familial early-onset, 136 sporadic early-onset
and 16 familial late-onset) from Spain and Uruguay using NGS. Follow-up genotyping was used to validate variants.
After genotyping additional controls, we performed segregation and functional analyses to determine the
pathogenicity of validated variants.
Results: We identified a novel G to T transition (g.38816G>T) in exon 6 of PSEN1 in a sporadic early-onset AD case,
resulting in a previously described pathogenic p.L173F mutation. A pathogenic p.L392V mutation in exon 11 was
found in one familial early-onset AD case. We also identified a novel CC insertion (g.10974_10975insCC) in exon 8
of GRN, which introduced a premature stop codon, resulting in nonsense-mediated mRNA decay. This GRN
mutation was associated with lower GRN plasma levels, as previously reported for other GRN pathogenic
mutations. We found two variants in MAPT (p.A152T, p.S318L) present only in three AD cases but not controls,
suggesting that these variants could be risk factors for the disease.
Conclusions: We found pathogenic mutations in PSEN1, GRN and MAPT in 2.33% of the screened cases. This study
suggests that pathogenic mutations or risk variants in MAPT and in GRN are as frequent in clinical AD cases as
mutations in APP, PSEN1 and PSEN2, highlighting that pleiotropy of MAPT or GRN mutations can influence both FTD
and AD phenotypic traits.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia, affecting more than 13% of individuals age 65
years or older and 30% to 50% of individuals age 80 or
older [1,2]. The number of affected individuals is esti-
mated to double by 2025; thus, AD is rapidly becoming
a serious threat to health care in developed countries
[2]. Since the number of patients and health-care costs
are projected to increase significantly, effective therapies
are urgently needed. Understanding how genetic risk
factors affect the disease process will help to identify
novel targets for therapies, to elucidate the nature of
aging, and to extend the healthy active life span.
AD is often classified on the basis of the age at onset
(AAO); early-onset AD (EOAD) is defined as AAO of not
more than 65 years, and late-onset AD (LOAD) is defined
as AAO of more than 65 years. Even though 99% of AD
cases are late-onset, studies of rare autosomal dominant
familial EOAD have provided valuable insights into the
pathogenesis of AD. Mutations in amyloid-b precursor
protein (APP), presenilin 1 (PSEN1), and presenilin 2
(PSEN2) were initially discovered in familial EOAD,
although additional studies have also identified pathogenic
mutations in these genes in late-onset families in addition
to the APOE4 allele [3-9]. Progranulin (GRN) and micro-
tubule-associated protein tau (MAPT) mutations are asso-
ciated with familial frontotemporal dementia, but recently
some have also been found in clinically diagnosed AD
cases [10,11], and a recent study suggested that mutations
inMAPT and GRN can be found in clinical AD with a fre-
quency comparable to that of mutations in APP, PSEN1,
and PSEN2 [7].
In this study, we aimed to examine the frequency of
causative mutations in autosomal dominant dementia
genes in independent clinical series from Spain and
Uruguay. We performed pooled-DNA sequencing in 172
AD cases in APP, PSEN1, PSEN2, GRN, and MAPT in
order to identify known pathogenic mutations and
potentially functional novel variants associated with dis-
ease risk. For those validated variants, follow-up geno-
typing was conducted in additional AD cases and non-
demented older controls with Spanish ancestry to infer
and compare mutation frequencies. We also genotyped
available relatives of the mutation carriers to determine
whether these mutations segregate with the diagnosis of
AD (Figure 1). Finally, enzyme-linked immunosorbent
assay (ELISA) was performed to test the association




DNA was collected from subjects of Spanish descent who
were recruited between 2000 and 2010 from the
departments of neurology of the collaborating centers
from Spain (n = 161) and Uruguay (n = 11). Samples
were selected from individuals with neuropathologically
confirmed AD or from individuals with the earliest AAO
along with a diagnosis of probable AD within a family.
The cohort included 15 (8.98%) familial EOAD, 136
(81.44%) sporadic EOAD, and 16 (9.58%) familial LOAD
cases and five others who were autopsy-confirmed AD
cases (Table 1). Diagnosis of probable AD was made in
accordance with standard clinical research criteria [12].
All individuals gave their written informed consent for
participating in the study, which was approved by the
institutional review board of Washington University in
St. Louis.
Pooled sequencing
Pooled-DNA sequencing was performed as previously
described [7,13]. The concentration of genomic DNA was
quantified by Quant-iT™ PicoGreen (Invitrogen Corpora-
tion, Carlsbad, CA, USA) reagent, and normalized
amounts of individual DNA samples were pooled. A single
DNA pool with 172 individuals was used as a template for
polymerase chain reaction (PCR) amplification of coding
regions of genes APP, PSEN1, PSEN2, MAPT, and GRN.
PRIMER3 software was used to design the primers for
amplification of each exon. To ensure complete coverage
of each exon, primers were at least 50 base pairs (bp) from
the intron-exon boundary. Pfu (Agilent Technologies,
Santa Clara, CA, USA) enzyme was used for all PCRs to
reduce the likelihood of PCR-induced sequence variants.
After PCR amplification of selected genomic regions, each
PCR product was purified by using QIAquick PCR (Qia-
gen Inc., Valencia, CA, USA) purification kits and quanti-
fied by using Quant-iT™ PicoGreen reagent. The PCR
products were combined into one pool in equimolar
amounts and ligated by using T4 ligase and T4 Polynu-
cleotide Kinase [14]. At this stage, negative control and
positive control amplicons were also added to the pool to
generate the error model and to construct the optimal sig-
nificant cutoff, respectively. Ligated concatemers were ran-
domly fragmented by sonication and prepared for Illumina
sequencing on an Illumina HiSeq2000 (Illumina, Inc., San
Diego, CA, USA) in accordance with the protocol of the
manufacturer. The fold coverage necessary to achieve the
optimal positive predictive value for the SNP-calling algo-
rithm was calculated, and a sequencing coverage of 30X
per haploid genome was targeted in this study, consistent
with the previous finding [14]. Two lanes of Illumina
HiSeq2000 sequencing were run to obtain a minimum of
30-fold coverage per allele.
Sequencing analysis
Sequencing reads (42-bp reads) were mapped back to
the reference sequence (GRCh37/hg19) allowing up to
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three mismatches by using an alignment algorithm
developed by Vallania and colleagues [14]. To determine
the sensitivity and specificity of this method, positive
and negative control vectors were included as PCR pro-
ducts in the pooled-DNA sequencing protocol described
above. The negative control reads were used to build up
the error model used in the variant calling step, whereas
the positive control reads were used to calculate the sig-
nificant cutoff for optimizing specificity and sensitivity
of the analysis. The SPLINTER (short indel prediction
by large deviation inference and nonlinear true fre-
quency estimation by recursion) program was used to
predict and quantify short insertions, deletions, and sub-
stitutions present in the pool. The segregated variants
were called by comparing the observed frequency vector
to the expected frequency vector calculated by the error
model. The maximum likelihood method was used to
estimate variant frequencies in the pool samples. SIFT2
Figure 1 Schematic of the study design. Pooled-DNA sequencing was performed in a single DNA pool of 172 individuals to identify known
pathogenic or novel functional variants by using Illumina HiSeq 2000. The SPLINTER software was used to call the variants. High-confident variants
were selected for Sequenom genotyping. For those validated functional variants, follow-up genotyping was performed in large case-control series
to infer and compare the frequencies. Segregation analysis was then performed to determine whether disease status segregates with risk alleles.
Enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the impact of novel GRN splice-site mutation on the changes of GRN plasma
levels. GRN, progranulin; SPLINTER, short indel prediction by large deviation inference and nonlinear true frequency estimation by recursion.
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was used to predict the effect of variants on protein
structure and function, and the Alzheimer Disease &
Frontotemporal Dementia (AD&FTD) mutation data-
base [15] was used to annotate the known pathogenic
variants. The Exome Variant Server (EVS) [16], Seattle-
Seq Annotation [17], and 1000 Genomes Project were
finally used to exclude known variants. Novel and
potentially functional variants were selected for direct
genotyping by using Sequenom iPLEX (Sequenom, San
Diego, CA, USA).
Genotyping and segregation analysis
All rare (minor allele frequency of less than 5%) mis-
sense, splice-site, and previously identified pathogenic
variants called in the pooled-DNA sequencing were gen-
otyped by using Sequenom iPLEX in accordance with
standard protocols. We genotyped validated variants in
all available family members to determine whether these
variants segregate with disease status. Common and
synonymous variants were not followed up.
GRN plasma level measurement
GRN plasma levels were measured in duplicate by using
an ELISA kit (Human Progranulin ELISA Kit; AdipoGen
Inc., Seoul, Korea).
Results
To identify known pathogenic mutations and novel rare
variants, pooled-DNA sequencing was performed for the
coding exons and their corresponding flanking regions
for APP, PSEN1, PSEN2, MAPT, and GRN in a total of
15 (8.98%) familial EOAD, 136 (81.44%) sporadic
EOAD, 16 (9.58%) familial LOAD, and five autopsy-con-
firmed AD cases (Table 1). For familial cases, a single
index case per family was sequenced. Seventy exons cov-
ering 45.3 kb of the target region of APP, PSEN1,
PSEN2, GRN, and MAPT were PCR-amplified by using
specific primers and then pooled in equimolar amounts.
The pooled amplicons were concatenated and sheared
to construct libraries and then sequenced on Illumina
HiSeq2000 by using two lanes.
We used the SPLINTER software to perform align-
ment and call rare variants in the pooled samples [14].
Sequencing reads were mapped back to the reference
genome (GRCh37/hg19) by gapped alignments allowing
up to 3-bp mismatches by using the SPLINTER aligner.
The Illumina sequencing produced 181,854,451 reads in
two lanes, and the aligner was able to map 155,431,194
reads (85.5%) back to the reference, resulting in an aver-
age 149.8-fold coverage per amplicon (corresponding to
143.5-fold coverage per allele).
Since our goal was to identify novel or functional rare
variants, 12 missense, splice-site, or previously con-
firmed pathogenic variants were selected for direct gen-
otyping by using Sequenom iPLEX (Table 2). These 12
variants were found in 34 out of 172 (19.77%) AD cases
and 12 out of 139 (8.63%) non-demented older controls
of Spanish descent (Table 2).
Four missense mutations (p.M139T, p.L173F, p.E318G,
and p.L392V) in PSEN1 were validated (Table 2). The
p.M139T mutation located in exon 5 of PSEN1 and the
p.L392V mutation in exon 11 have been shown to be
pathogenic in previous studies [5,18-24]. The p.M139T
carrier, who had a ε3/ε3 genotype, was a sporadic EOAD
case with an AAO of 47.5 years, which is close to the
mean AAO of disease in three previously reported
families (one French family and two independent Spanish
families). The p.L392V mutation, which has been identi-
fied in five families (one Italian family, one French, one
Japanese, and two unknown), was confirmed in a familial
EOAD case with the APOE ε3/ε4 genotype and AAO of
42.5, which is similar to the mean AAO in these five
families [5,18,19,22-24]. We also found a novel G-to-T
transition (g.38816G>T) in exon 6 of PSEN1, resulting in
a previously described pathogenic p.L173F missense
mutation [25]. The carrier of the p.L173F mutation in
our study, who was an APOE ε3/ε3 carrier, had an AAO
of 50.5 years, which is close to the mean AAO in the
family reported by Kasuga and colleagues [25]. The
p.L173F mutation was shown to be associated with
Table 1 Demographic characteristics of the cohort of 172
sequenced samples
Demographic characteristics






Familial early-onset AD (onset ≤65 years) 15 8.98%
Sporadic early-onset AD (onset ≤65 years) 136 81.44%
Familial late-onset AD (onset >65 years) 16 9.58%














AD, Alzheimer’s disease; APOE, apolipoprotein E.
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presenile dementia and parkinsonism [25]. The p.M139T
and p.L173F mutations in PSEN1 were not found in
any additional cases or the 459 Spanish controls. The
p.E318G mutation was a low-frequency polymorphism
observed at equal frequencies in patients and unaffected
controls in several previous studies [26-28]. The p.E318G
frequency in our study was higher in controls (2.16%, 3
out of 139) than in AD cases (1.14%, 2 out of 176), sug-
gesting that p.E318G might not be a risk factor for clini-
cal AD.
We also found a novel GRN CC insertion, g.10974_
10975insCC (Ile256IlefsX27), which was not present in the
AD&FTD database, 1000 Genomes Project, SeattleSeq, or
EVS (Figure 2). The CC insertion is a frameshift mutation
located in exon 8 of GRN, introducing a premature stop
codon 27 amino acids after the insertion site (Ile256I-
lefsX27). Considering other frameshift mutations in GRN
[29-33], we predicted that the mutant allele will be
degraded by nonsense-mediated decay, resulting in a loss
of one functional allele. To confirm that the novel GRN
frameshift mutation (Ile256IlefsX27) was related to the
diagnosis of AD, we performed segregation analysis, geno-
typing of additional Spanish controls, and functional ana-
lysis. The proband, the carrier of the GRN mutation with
the APOE ε3/ε3 genotype, had an AAO of 60.5 years and
was diagnosed with probable AD on the basis of interna-
tional criteria [12]. One of the proband’s siblings, who had
a diagnosis of probable AD, is also a carrier of the muta-
tion. Two other non-demented siblings of the proband did
not carry the variant. The GRN frameshift mutation was
absent in 449 older healthy Spanish controls.
Previous studies have shown that individuals with
pathogenic GRN mutations have lower GRN plasma
levels [30,31,34-38]. Therefore, we tested whether the
GRN g.10974_10975insCC mutation was associated with
low GRN plasma levels. The GRN plasma levels were
measured in 18 individuals, including two non-demented
siblings of the proband who did not carry the mutation,
11 carriers of a previously identified GRN mutation (as
positive controls), and five family members who were
non-carriers for GRN mutations [35,39,40]. The GRN
g.10974_10975insCC mutation carrier had an average
GRN plasma level of 0.125 ng/μL, which is very close to
0.116 ng/μL, the average GRN plasma level of a known
GRN mutation carrier (Figure 3). The two siblings of the
carrier of the GRN g.10974_10975insCC mutation had an
average GRN plasma level of 0.463 ng/μL, which is close
to the mean GRN plasma level for the five family mem-
bers who were non-carriers of the GRN mutation (0.504
ng/μL). Together, these results confirm that the GRN
g.10974_10975insCC mutation is pathogenic.
Seven missense variants in MAPT were further vali-
dated in our study: five in exon 4A (p.S318L, p.G213R, p.
V224G, p.Q230R, and p.A297V), one in exon 7 (p.
A152T), and one in exon 10 (p.V287I). The frequency of
each variant in cases and controls is listed in Table 2. p.
G213R, p.V224G, p.Q230R, and p.S318L reside in exon
4A of MAPT and are present in SeattleSeq, EVS, or 1000




AA change rs ID Codonchange AD&FTDa Alzheimer’s disease cases Controls
Count (%) AAO range,
years
Diagnosesb Count (%)
GRN-8 Ile256IlefsX27 - [-/CC] - 1/176 (0.57) 60.5 1 FL 0/459 (0)
MAPT-10 GTC-aTC 149280278 V287I - 2/176 (1.14) 64.5-70.5 1 SE and 1 FL 0/534 (0)
MAPT-4A TCG-TtG 73314997 S318L - 1/176 (0.57) 64.5 1 SE 0/139 (0)
MAPT-4A GGG-aGG 76375268 G213R - 1/176 (0.57) 64.5 1 SE 0/139 (0)
MAPT-4A GTC-GgC 141120474 V224G - 3/176 (1.7) 58.5-72.5 1 FE and 2 FL 1/139 (0.72)
MAPT-4A CAA-CgA 63750072 Q230R - 18/176
(10.23)
50.5-83.5 1 AC, 2 FE, 2 FL, and 13
SE
8/139 (5.8)
MAPT-4A GCC-GtC - A297V - 1/176 (0.57) 59.5 1 FE 0/139 (0)
MAPT-7 GCC-aCC 143624519 A152T - 2/176 (1.14) 57.5 1 AC and 1 SE 0/139 (0)
PSEN1-5 ATG-AcG 63751106 M139T Pathogenic 1/176 (0.57) 47.5 1 SE 0/459 (0)
PSEN1-6 TTG-TTt - L173F Pathogenic 1/176 (0.57) 50.5 1 SE 0/459 (0)
PSEN1-9 GAA-GgA 17125721 E318G Not
pathogenic
2/176 (1.14) 56.5-65.5 2 SE 3/139 (2.2)
PSEN1-11 CTG-gTG 63751416 L392V Pathogenic 1/176 (0.57) 42.5 1 FE Not
available
aAlzheimer Disease & Frontotemporal Dementia mutation database [15]. bThis column summarizes the status of carriers in Alzheimer’s disease cases. AAO, age at
onset; AC, autopsy-confirmed Alzheimer’s disease; FE, familial early-onset Alzheimer’s disease; FL, familial late-onset Alzheimer’s disease; GRN, progranulin; MAPT,
microtubule-associated protein tau; PSEN1, presenilin 1; SE, sporadic early-onset Alzheimer’s disease; SL, sporadic late-onset Alzheimer’s disease.
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Genomes Project, suggesting that they do not affect risk
for AD. The p.A297V mutation also located in exon 4A
was not found in any annotation tool, and thus the func-
tional role of p.A297V remains unclear. The p.A152T
variant located in exon 7 was suggested in a recent study
to be a risk factor for FTD-spectrum and AD in a total of
15,369 subjects [41]. Another recent study shows that the
p.A152T mutation increases risk for developing neurode-
generative diseases by influencing tau accumulation [42].
We found two p.A152T carriers among the cases (one
with ε3/ε3 and one with ε4/ε4 genotype) and none in the
controls. Segregation analysis showed that the healthy
69-year-old sibling of the AD proband did not carry the
p.A152T mutation. No family history for the other
MAPT p.A152T carrier was reported, but autopsy was
available for this individual. Fresh brain weight was 924
g. A macroscopic examination revealed moderate global
cortical atrophy, and serial coronal sections of the left
hemisphere showed moderate ventricular dilatation and
atrophy of the medial temporal lobe, particularly in its
anterior segment. A histological examination based on
immunohistochemistry for tau and beta-amyloid revealed
a high density of neuritic plaques in associative isocorti-
cal areas, a dense distribution of neurofibrillary tangles
consistent with Braak stage VI, and moderate amyloid
angiopathy. Additionally, immunostaining for alpha-
synuclein displayed abundant Lewy bodies and neurites
at the amygdaloid complex and enthorrinal cortex and a
moderate density of inclusions in the parahippocampal
and cyngular cortices and in brainstem nuclei. These
findings are consistent with a neuropathological diagno-
sis of Alzheimer’s type changes with a high probability of
disease, combined with Lewy type pathology of the limbic
predominant subtype [43].
These results suggest that p.A152T contributes to an
increased risk associated with clinical AD. The p.S318L
Figure 2 The transcript of the novel GRN mutation. A splice-site mutation with a CC-insertion (g.10974_10975insCC) in GRN exon 8 results in
a premature stop codon and nonsense-mediated decay of the resultant mRNA. GRN, progranulin.
Figure 3 Enzyme-linked immunosorbent assays comparing
GRN plasma levels between GRN mutation carriers and
controls. Measurement of GRN plasma levels for a known GRN
mutation (left) and the novel GRN mutation (right), Ile256IlefsX27,
observed in our study compared with Alzheimer’s disease cases and
non-demented older controls. GRN, progranulin; mut, mutant; wt,
wild-type.
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variant, located in exon 10 of MAPT, was found in two
cases (one with ε3/ε3 and one with ε3/ε4 genotype) and
none of 534 ethnicity-matched controls, suggesting that
p.S318L might increase the risk for clinical AD. How-
ever, studies with a larger sample size are needed to
confirm its role in AD risk.
Discussion
Our study has shown that pooled-DNA sequencing can
effectively identify known and novel pathogenic variants.
So far, around 344 different mutations have been identi-
fied in APP, PSEN1, PSEN2, GRN, and MAPT according
to the AD&FTD mutation database. In this study, we
identified four pathogenic variants (p.M139T, p.L173F,
and p.L392V in PSEN1 and g.10974_10975insCC in
GRN), two of which were novel (p.L173F in PSEN1 and
g.10974_10975insCC in GRN). These four pathogenic
variants explain 2.33% of our clinical AD cases. How-
ever, the lack of additional familial cases prevents us
from performing segregation analysis for other variants
(MAPT p.V287I and p.A152T), and therefore their effect
on risk for disease is unclear. Additional genetic and
functional analyses are required to confirm the effect of
these variants on risk for AD.
On the other hand, for the GRN g.10974_10975insCC
insertion, we confirmed that this novel mutation segre-
gates with disease status. This rare insertion mutation was
not found in 459 older healthy Spanish controls. In addi-
tion, our results from functional analyses were concordant
with the known biological function of other known patho-
genic GRN variants. The GRN frameshift mutation creates
a premature stop codon that results in nonsense-mediated
decay leading to a decrease in GRN mRNA levels and pro-
tein levels in plasma and cerebrospinal fluid [7,29-33]. We
found that the GRN g.10974_10975insCC mutation car-
riers had extremely low plasma GRN levels, confirming
the functional role of this novel mutation.
In MAPT, we found the p.A152T variant in exon 7 in
two cases and no controls. Recently, this variant was
reported to be a risk factor for FTD and AD [41]. The
p.A152T variant was found in 0.69% of AD cases and 0.3%
of controls (odds ratio = 2.3, P value = 0.004) [41]. In our
segregation analysis, p.A152T was absent in the healthy
69-year-old sibling of the proband, suggesting that
p.A152T does segregate with disease in this family. The
p.V287I mutation was found in one chromosome out of
10,753 (corresponding to a frequency of 0.0186%) in the
EVS database. We found this variant in two cases (1.14%),
which is a much higher frequency than that observed in
the EVS database, suggesting that this variant could be
associated with increased risk for disease. So far, all of the
MAPT variants in exon 4A were reported to be non-
pathogenic (six out of six) in the AD&FTD database
[44-47]. In addition, previous studies have shown that the
MAPT exon 4A is not expressed in the adult human cere-
bral cortex [48,49]. Although all six of the MAPT variants
in exon 4A found in this study (including p.S318L,
p.G213R, p.V224G, p.Q230R, and p.A297V) have higher
frequencies in cases than in controls, these variants are
more likely to be non-pathogenic according to previous
findings and records.
Conclusions
In summary, we have identified two novel pathogenic
variants: one in PSEN1 gene and the other in GRN. We
also conducted functional studies to validate the patho-
genicity of the GRN variant. Our findings are consistent
with those that were previously reported by our group in
a different population [7] and that concluded the follow-
ing: (a) there are likely more novel pathogenic variants
causing an AD phenotype to be discovered in the AD
(APP, PSEN1, and PSEN2) and FTD (MAPT and GRN)
genes, (b) pathogenic variants located in such ‘neurode-
generation’ genes could be responsible for both EOAD
and LOAD, and (c) mutations in GRN and MAPT, which
have been considered traditionally ‘FTD genes’, can be
present in individuals with a clinical presentation indis-
tinguishable from that of typical AD. Pathological infor-
mation for the individual carriers for the novel GRN
insertion and the novel MAPT variants was not available,
so the AD diagnosis was based solely on clinical assess-
ment. Given other reports, it is more likely that these
individuals are amnestic FTD cases but had a clinical pre-
sentation indistinguishable from that of AD [7]. Identifi-
cation of mutations in MAPT and GRN can help to make
a more accurate diagnosis in these individuals. These
results highlight the necessity of screening both AD and
FTD genes when autopsy confirmation of diagnosis is
unavailable in demented individuals.
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